Nasdaq · Biotech stocks database
ABUS (Arbutus Biopharma Corporation) stock: $4.07, $623.1M market cap, $337.5M cash, $288.6M EV, $864.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).
Source: 10-K FY2025 via SEC EDGAR
| Cash | $337.5M |
|---|---|
| Debt | $0.0M |
| Royalty-sale liability | $3.0M |
| Net cash | $337.5M |
| Enterprise value | $288.6M |
| Basic shares | 153.3M shares |
| Fully diluted shares | 212.4M shares |
| Fully diluted market cap | $864.3M |
| Cash per share | $2.20 |
| Quarterly burn | $6.0M |
| Cash runway | 15.4 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.
Royalty-sale liability as of 2026-09-30 (10-Q); included in enterprise value.
Cap table as of 2026-08-10.
Loading ABUS daily closes…